Clinical Professor of Neurology, Nova SE University Fort Lauderdale, Fl
Neurology
Carl Sadowsky practices Neurology. He went to Weill Cornell Medical College of Cornell University. Weill Cornell Medical College of Cornell University is ranked 18 in research and 49 in primary care medicine He has 8 awards "Gulfstream FL-Palm Beach", "America's Top Doctors", "CMS Meaningful Use Stage 1 Certification", "SouthFloridaCEO: Top Doctors", "Miami Metro City Guide: Top Doctors", "Top Doctors: Florida", "Top MD" and "Super Doctor". Doctor Carl H. Sadowsky, MD is a published physician. He published 34 publications, including: 'Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer disease.' He accepts Medicare payments and is registered with Medicare.gov.
Publications
- Phase 3 trial of flutemetamol labeled with radioactive fluorine 18 imaging and neuritic plaque density.
- Evaluating Response to High-Dose 13.3 mg/24 h Rivastigmine Patch in Patients with Severe Alzheimer's Disease.
- A 24-Week, Open-Label Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of 13.3 mg/24 h Rivastigmine Patch in Patients With Severe Alzhei...
- Florbetapir F 18 amyloid PET and 36-month cognitive decline:a prospective multicenter study.
- Efficacy of higher-dose 13.3 mg/24 h (15 cm(2) ) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
- Neuropathologic heterogeneity does not impair florbetapir-positron emission tomography postmortem correlates.
- A 24-Week, Randomized, Controlled Trial of Rivastigmine Patch 13.3 mg/24 h Versus 4.6 mg/24 h in Severe Alzheimer's Dementia.
- Amyloid deposition detected with florbetapir F 18 ((18)F-AV-45) is related to lower episodic memory performance in clinically Normal older individuals.
- Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's Disease dementia, mild cognitive impairment, and normal aging.
- Potential impact of amyloid imaging on diagnosis and intended management in patients with Progressive cognitive decline.
- Apolipoprotein E ?4 and age effects on florbetapir positron emission tomography in healthy aging and Alzheimer Disease.
- Predictors of sustained response to rivastigmine in patients with Alzheimer's Disease: a retrospective analysis.
- Safety and efficacy of rivastigmine in patients with Alzheimer's Disease not responding adequately to donepezil: an open-label study.
- The validation of a caregiver assessment of Dementia: the Dementia Severity Scale.
- Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.
- Rivastigmine from capsules to patch: therapeutic advances in the management of Alzheimer's Disease and Parkinson's Disease dementia.
- Office-based treatment of acute Migraine with dihydroergotamine mesylate.
- Effect of tacrine on language, praxis, and noncognitive behavioral problems in Alzheimer Disease.
- Spinal cord injury.
- Concomitant administration of antiemetics is not necessary with intramuscular dihydroergotamine.
- A controlled trial of tacrine in Alzheimer's Disease. The Tacrine Study Group.
- DHEA treatment of Alzheimer''s Disease: a randomized, double-blind, placebo-controlled study.
- Rivastigmine transdermal system for the treatment of mild to moderate Alzheimer''s Disease.
- Switching from oral cholinesterase inhibitors to the rivastigmine transdermal patch.
- Safety and tolerability of rivastigmine transdermal patch compared with rivastigmine capsules in patients switched from donepezil: data from three clinical trials.
- A systematic review of the effectiveness of rivastigmine for the treatment of behavioral disturbances in Dementia and other neurological disorders.
- A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer''s Disease--rivastigmine patch versus capsule.
- A cost effective method of identifying and recruiting persons over 80 free of Dementia or mild cognitive impairment.
- Safety and tolerability of the rivastigmine patch: results of a 28-week open-label extension.
- Magnetic resonance imaging and neuropsychological results from a trial of memantine in Alzheimer's Disease.
- Switching from oral donepezil to rivastigmine transdermal patch in Alzheimer''s Disease: 20-week extension phase results.
- Use of florbetapir-PET for imaging beta-amyloid pathology.
- Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer''s Disease.
Schools
Joan Sanford I Weill Medical College Of Cornell University
Mary Hitchcock Memorial Hospital
Procedures Preformed
- EEG (Electroencephalogram)
Conditions Treated
- Alzheimer's Disease
- Ataxia
- Cerebral Artery Thrombosis
- Cerebrovascular Disease
- View All
Doctors Specialties
Accepted Insurances
Awards
- Gulfstream FL-Palm Beach
- America's Top Doctors
- CMS Meaningful Use Stage 1 Certification
- SouthFloridaCEO: Top Doctors
- Miami Metro City Guide: Top Doctors
- Top Doctors: Florida
- Top MD
- Super Doctor
Education
-
Dartmouth-Hitchcock Medical Center
-
Weill Cornell Medical College of Cornell University
Drug Facts
| NPI NUMBER |
|
1588776983 |
| NPPES Provider LastName |
|
SADOWSKY |
| NPPES Provider FirstName |
|
CARL |
| NPPES Provider ZIPCode |
|
33407 |
| NPPES Provider State |
|
FL |
| Specialty Description |
|
Neurology |
| Total Claim Count |
|
1127.0 |
| Distinct Opioid Count |
|
0.0 |
| Opioid Claim Count |
|
0.0 |
| Percent Opioid Claims |
|
0.0 |
Helpful Reviews
Give
Anonymous Review
Medicare Facts
| National Provider Identifier [NPI] |
1588776983 |
| Last Name Of The Provider |
SADOWSKY |
| First Name Of The Provider |
CARL |
| View All |
|
Similar Doctors
Doctor Directory | TOS | twitter | FB | Angel | blog
This Doctor is OpenDoctor Recommended.
